Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Incyte Corporation Call Center (ex-US) +800 00027423
eumedinfo@incyte.com


Incyte Corporation Call Center (US) 1.855.463.3463
medinfo@incyte.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Back

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Recruiting

Open to: ALL

Age: 18.0 - N/A

Newcastle Upon Tyne Manchester Cambridge London London

Medical Conditions

Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jul 2023 Jan 2027

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : INCA33890 will be administered at protocol defined dose.

Intervention Arm Group : Part 1a - Dose Escalation Monotherapy;Part 1b-Dose Expansion Monotherapy;Part 2a - Dose Escalation Combination Therapy - Group 1;Part 2a - Dose Escalation Combination Therapy - Group 2;Part 2a - Dose Escalation Combination Therapy - Group 3;Part 2a - Dose Escalation Combination Therapy - Group 4;Part 2b - Dose Expansion Combination Therapy - Group 1;Part 2b - Dose Expansion Combination Therapy - Group 2;Part 2b - Dose Expansion Combination Therapy - Group 3;Part 2b - Dose Expansion Combination Therapy - Group 4;

Intervention Type : DRUG
Intervention Description : Bevacizumab will be administered at protocol defined dose.

Intervention Arm Group : Part 2a - Dose Escalation Combination Therapy - Group 1;Part 2a - Dose Escalation Combination Therapy - Group 2;Part 2a - Dose Escalation Combination Therapy - Group 3;Part 2b - Dose Expansion Combination Therapy - Group 1;Part 2b - Dose Expansion Combination Therapy - Group 2;Part 2b - Dose Expansion Combination Therapy - Group 3;

Intervention Type : DRUG
Intervention Description : FOLFIRI will be administered at protocol defined dose.

Intervention Arm Group : Part 2a - Dose Escalation Combination Therapy - Group 2;Part 2b - Dose Expansion Combination Therapy - Group 2;

Intervention Type : DRUG
Intervention Description : FOLFOX will be administered at protocol defined dose.

Intervention Arm Group : Part 2a - Dose Escalation Combination Therapy - Group 3;Part 2b - Dose Expansion Combination Therapy - Group 3;

Intervention Type : DRUG
Intervention Description : Cetuximab will be administered at protocol defined dose.

Intervention Arm Group : Part 2a - Dose Escalation Combination Therapy - Group 4;Part 2b - Dose Expansion Combination Therapy - Group 4;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Freeman Hospital Newcastle Upon Tyne Foundation Nhs Trust
    Newcastle Upon Tyne
    NE7 7DN
  • The Christie Nhs Foundation Trust Uk
    Manchester
    M20 4BV
  • Cambridge University Hospitals Nhs Foundation Trust
    Cambridge
    CB2 0QQ
  • Guys and St Thomas Nhs Foundation Trust
    London
    SE1 9RT
  • Imperial College Healthcare Nhs Trust - Hammersmith Hospital
    London
    W12 0HS

Incyte Corporation Call Center (US) 1.855.463.3463
medinfo@incyte.com


Incyte Corporation Call Center (ex-US) +800 00027423
eumedinfo@incyte.com



The study is sponsored by Incyte Corporation



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05836324
Last updated 11 June 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top